PFE vs. JNJ, MRK, ABBV, BMY, ZTS, RPRX, JAZZ, PRGO, CORT, and SUPN
Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation.
Johnson & Johnson has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
In the previous week, Johnson & Johnson had 4 more articles in the media than Pfizer. MarketBeat recorded 38 mentions for Johnson & Johnson and 34 mentions for Pfizer. Johnson & Johnson's average media sentiment score of 0.68 beat Pfizer's score of 0.60 indicating that Pfizer is being referred to more favorably in the news media.
Johnson & Johnson has a net margin of 45.26% compared to Johnson & Johnson's net margin of -0.56%. Pfizer's return on equity of 36.70% beat Johnson & Johnson's return on equity.
Johnson & Johnson currently has a consensus price target of $174.07, indicating a potential upside of 18.68%. Pfizer has a consensus price target of $35.86, indicating a potential upside of 25.11%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Pfizer is more favorable than Johnson & Johnson.
69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Pfizer received 404 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.06% of users gave Pfizer an outperform vote while only 64.93% of users gave Johnson & Johnson an outperform vote.
Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.9%. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 63 consecutive years and Pfizer has raised its dividend for 15 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.
Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Summary
Johnson & Johnson beats Pfizer on 12 of the 21 factors compared between the two stocks.
Get Pfizer News Delivered to You Automatically
Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
